Literature DB >> 8082077

The relationship between microscopic margins of resection and the risk of local recurrence in patients with breast cancer treated with breast-conserving surgery and radiation therapy.

S J Schnitt1, A Abner, R Gelman, J L Connolly, A Recht, R B Duda, T J Eberlein, K Mayzel, B Silver, J R Harris.   

Abstract

BACKGROUND: The relationships among the involvement of tumor at the final margins of resection, the presence of an extensive intraductal component (EIC), and the risk of local recurrence are important considerations in patients treated with conservative surgery and radiation therapy for early stage breast cancer but have not been defined adequately.
METHODS: Between 1982 and 1985, 885 patients were treated for clinical Stage I or II invasive breast cancer. The study population was limited to 181 patients with an infiltrating ductal carcinoma who received a radiation dose to the surgical site of 60 Gy or greater, whose final microscopic margins of resection were evaluable, and who had at least 5 years of follow-up. A positive margin was defined as tumor present at the inked margin of resection, a close margin as tumor within 1 mm of the inked margin, and a negative margin as no tumor within 1 mm of the inked margin. A focally positive margin was defined as tumor at the margin in three or fewer low-power fields. In 157 patients (87%), the tumor was evaluable for the presence or absence of an EIC. The median follow-up was 86 months.
RESULTS: In 12 of 181 patients (7%), a recurrence developed at or near the primary site (true recurrence/marginal miss [TR/MM]) within 5 years. The 5-year rate of TR/MM (with 95% confidence intervals) among patients with negative, close, focally positive, and more than focally positive margins was 0% (0-4%), 4% (0-20%), 6% (1-17%) and 21% (10-37%), respectively. Patients with positive margins also were more likely to have a distant failure within 5 years (14%, 8%, 25%, and 32% in the four groups, respectively). However, patients with positive margins more often had positive axillary lymph nodes than patients with negative or close margins (59% vs. 38%, P < 0.02). The 5-year rate of TR/MM was 20% for patients with an EIC-positive tumor and 7% for patients with an EIC-negative tumor. However, among the 127 patients with an EIC-negative tumor, the 5-year rate of TR/MM was less than 10% in all margin groups. Among the 30 patients with an EIC-positive tumor, the 5-year rate of TR/MM was 0% when margins were negative or close but 50% when margins were more than focally positive.
CONCLUSIONS: These results provide support for the use of breast-conserving surgery and breast irradiation in all patients with uninvolved margins, whether the tumor is EIC-positive or EIC-negative. This study suggests that breast-conserving therapy (including a radiation boost to the primary site) also may be a reasonable option for some patients with an EIC-negative tumor and margin involvement.

Entities:  

Mesh:

Year:  1994        PMID: 8082077     DOI: 10.1002/1097-0142(19940915)74:6<1746::aid-cncr2820740617>3.0.co;2-y

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  61 in total

1.  Telomere length variation in normal epithelial cells adjacent to tumor: potential biomarker for breast cancer local recurrence.

Authors:  Xin Zhou; Alan K Meeker; Kepher H Makambi; Ourania Kosti; Bhaskar V S Kallakury; Mary K Sidawy; Christopher A Loffredo; Yun-Ling Zheng
Journal:  Carcinogenesis       Date:  2011-11-09       Impact factor: 4.944

2.  Local Recurrence after Conservative Surgery for Breast Cancer.

Authors: 
Journal:  Breast Cancer       Date:  1996-06-28       Impact factor: 4.239

3.  Local Control and Cosmetic Outcome after Sector Resection with or without Radiation Therapy for Early Breast Cancer.

Authors: 
Journal:  Breast Cancer       Date:  1996-03-29       Impact factor: 4.239

4.  Current perceptions regarding surgical margin status after breast-conserving therapy: results of a survey.

Authors:  Alphonse Taghian; Majid Mohiuddin; Reshma Jagsi; Saveli Goldberg; Elizabeth Ceilley; Simon Powell
Journal:  Ann Surg       Date:  2005-04       Impact factor: 12.969

5.  [Prognostic and predictive factors of invasive breast cancer: update 2009].

Authors:  T Decker; D Hungermann; W Böcker
Journal:  Pathologe       Date:  2009-02       Impact factor: 1.011

6.  Cellular protein and mRNA expression patterns of matrix metalloproteinases-2, -3 and -9 in human breast cancer: correlation with tumour growth.

Authors:  Annette Lebeau; Claudia Müller-Aufdemkamp; Clarissa Allmacher; Ulrich Sauer; Andreas Nerlich; Ralf Lichtinghagen; Udo Löhrs
Journal:  J Mol Histol       Date:  2004-06       Impact factor: 2.611

7.  Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer.

Authors:  Meena S Moran; Stuart J Schnitt; Armando E Giuliano; Jay R Harris; Seema A Khan; Janet Horton; Suzanne Klimberg; Mariana Chavez-MacGregor; Gary Freedman; Nehmat Houssami; Peggy L Johnson; Monica Morrow
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-03-01       Impact factor: 7.038

8.  Breast MR imaging for the assessment of residual disease following initial surgery for breast cancer with positive margins.

Authors:  Julia Krammer; Elissa R Price; Maxine S Jochelson; Elizabeth Watson; Melissa P Murray; Stefan O Schoenberg; Elizabeth A Morris
Journal:  Eur Radiol       Date:  2017-05-31       Impact factor: 5.315

9.  Long-term results of breast conservation therapy for breast cancer.

Authors:  P T Neff; H D Bear; C V Pierce; M M Grimes; M D Fleming; J P Neifeld; D Arthur; J S Horsley; W Lawrence; M J Kornstein
Journal:  Ann Surg       Date:  1996-06       Impact factor: 12.969

10.  Scatter spectroscopic imaging distinguishes between breast pathologies in tissues relevant to surgical margin assessment.

Authors:  Ashley M Laughney; Venkataramanan Krishnaswamy; Elizabeth J Rizzo; Mary C Schwab; Richard J Barth; Brian W Pogue; Keith D Paulsen; Wendy A Wells
Journal:  Clin Cancer Res       Date:  2012-08-20       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.